Increased ornithine decarboxylase activity in kidneys undergoing hypertrophy in experimental diabetes.
Renal hypertrophy and hyperfiltration are early manifestations of human and experimental diabetes that may contribute to the late development of diabetic nephropathy. The biochemical events resulting in kidney growth in the diabetic state are completely unknown. Since growth of various tissues is accompanied by increased formation of polyamines, we studied whether polyamines were involved in the growth of the kidney observed in diabetic rats. This was done by measuring the activity of the rate-limiting enzyme in the polyamine pathway (ornithine decarboxylase; ODC) in kidneys from control, diabetic and insulin-treated diabetic animals. The ODC activity in the kidney was increased in the diabetic animals with a maximal rise 24 h after diabetes induction (6-fold, P less than 0.01); the activity thereafter declined. However, on day 14 the activity was still significantly elevated (2.5-fold, P less than 0.05). In insulin-treated diabetic animals the kidney ODC activity was only increased 3-fold (P less than 0.05) after 24 h, and for the rest of the study period the activity was about 1.8-fold higher than in control rats. After 14 days the kidneys from diabetic rats were significantly larger than kidneys from both control and insulin-treated diabetic rats, 1066 +/- 43 mg vs. 904 +/- 16 mg and 959 +/- 36 mg, respectively (P less than 0.01). For comparison, the ODC activity was also investigated in muscle. However, in muscle from diabetic animals the ODC activity declined steadily during the 14 days to 34% of control values (P less than 0.01), and insulin treatment completely normalized the ODC activity in muscle.(ABSTRACT TRUNCATED AT 250 WORDS)
Pedersen
S B
SB
University Clinic of Internal Medicine, Division of Endocrinology and Metabolism, Aarhus Amtssygehus, Denmark.
Flyvbjerg
A
A
Grønbaek
H
H
Richelsen
B
B
D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy / Q000201:enzymology*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000201:enzymology*; D003928:Diabetic Nephropathies / Q000201:enzymology*; D006984:Hypertrophy / Q000201:enzymology; D007328:Insulin / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use; D007668:Kidney / Q000201:enzymology* / Q000473:pathology; D008297:Male; D009124:Muscle Proteins / Q000032:analysis; D009132:Muscles / Q000201:enzymology; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D011919:Rats, Inbred Strains
D001786:Blood Glucose; D007328:Insulin; D009124:Muscle Proteins